Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Journal article

Open access

Peer reviewed

Leukemia, Vol.30(12), pp.2397-2401

01/12/2016

PMCID: PMC5155032

PMID: 27499140

Abstract

Hematology

Life Sciences & Biomedicine

Oncology

Science & Technology

url

https://doi.org/10.1038/leu.2016.221View

Published (Version of record) Open

1 Record Views

Title: Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
Creators - without role: S. Z. Gadhoum - King Abdullah University of Science and Technology
N. Y. Madhoun - King Abdullah University of Science and Technology
A. F. Abuelela - King Abdullah University of Science and Technology
J. S. Merzaban - King Abdullah University of Science and Technology
Publication Details: Leukemia, Vol.30(12), pp.2397-2401
Publisher: Springer Nature
Number of pages: 6
Identifiers: 9941639108331
Academic Unit: King Abdullah University of Science & Technology
Language: English
Resource Type: Journal article